$10 Billion Deal, page-26

Commercialisation of the platform doesn't necessarily mean a buyout of which you constantly refer. You are inferring too much in my opinion, and I believe they are only referencing the Hep and Hiv (I could be wrong though). Any number of pharmaceutical companies may offer a partnership that carries a compound through to Phase III and if successful, Biotron would most likely end up with royalties thereafter. I fear you are leading people down the garden path....the figures you keep sprouting make a modicum of sense if Biotron becomes a takeover target. However, a JV will only make them economically viable while they continue their research on their other compounds within the library. In my experience, news of JV's have meant transient spikes in the SP....the real money will only come through a takeover offer.